NTLA
INTELLIA Lands Up to $400M Non-Dilutive Debt Facility From OrbiMed
The CRISPR company drew $75 million at closing, with $325 million more tied to milestones ahead of a planned U.S. launch of lonvo-z in hereditary angioedema.
NTLA
Market-moving news on Intellia Therapeutics (NASDAQ: NTLA): filings, earnings, deals and other events, from REDFILED.